Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taxotere and Carboplatin in Relapsed Ovarian Cancer
NCT00090610Phase 2Completed
- Sponsor
- Duke University
- Start
- Oct 2003
- Primary completion
- Mar 2009
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel and carboplatin in ovarian cancer (2 arms), sponsored by Duke University. Primary endpoint: Progression-free Survival. Started Oct 2003; status: completed.
02
Drugs
docetaxelcarboplatin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00090610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00090610.